East Hanover, NJNCT07635316Now EnrollingIRB Ready

Gastroenteropancreatic Neuroendocrine Tumor Clinical Trial in East Hanover, NJ

Access cutting-edge gastroenteropancreatic neuroendocrine tumor treatment through this clinical trial at a research site in East Hanover. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this East Hanover location

Preparing your pre-screening questions…

Expert Care in East Hanover

Access gastroenteropancreatic neuroendocrine tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastroenteropancreatic neuroendocrine tumor treatment provided free

Apply for This East Hanover Location

Check if you qualify for this gastroenteropancreatic neuroendocrine tumor clinical trial in East Hanover, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to East Hanover

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit East Hanover site if eligible
  4. 4Begin participation

About This Gastroenteropancreatic Neuroendocrine Tumor Study in East Hanover

This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Patients with ≥1 International Classification of Diseases Clinical Modification, 10th revision (ICD-10-CM) diagnosis code for GEP-NET between 01 January 2018 and 31 December 2025. The date of the first such claim will be defined as the diagnosis date.
Initiation of first-line (1L) systemic therapy (i.e., somatostatin analogs \[SSAs\], targeted therapy, peptide receptor radionuclide therapy \[PRRT\], chemotherapy) indicated for GEP-NET on or after the date of diagnosis. The date of treatment initiation will be defined as the index date.
Patients ≥18 years of age on the index date
Patients with ≥12 months (360 days) of continuous data availability (proxy for continuous health plan enrollment) prior to the index date, defined as:
≥1 medical and pharmacy claim \>12 months prior to the index date; AND
≥1 medical and pharmacy claim within the first 6 months of the 12-month period prior to the index date; AND
≥1 medical and pharmacy claim during the last 6 months of the 12-month period prior to the index date; AND
Patients with ≥1 month (30 days) of continuous data availability (proxy for continuous health plan enrollment) following the index date, defined as:
≥ 1 pharmacy dispensing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date
≥ 1 provider prescribing a GEP-NET treatment at any time during the post-index period, including the index date, reports data during the first month following the index date

Exclusion Criteria

Patients with evidence of GEP-NET prior to the diagnosis date within the study period
Patients with evidence of GEP-NET treatment prior to the index date within the study period
Patients with missing or invalid age or sex
Patients with other primary malignancies during the 12-month pre-index period
Patients with invalid death date (i.e., death date ≤ index date)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in East Hanover?

Yes, this clinical trial (NCT07635316) has an active research site in East Hanover, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastroenteropancreatic Neuroendocrine Tumor Treatment Options in East Hanover, NJ

If you're searching for gastroenteropancreatic neuroendocrine tumor treatment options in East Hanover, NJ, this clinical trial (NCT07635316) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our East Hanover research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastroenteropancreatic neuroendocrine tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastroenteropancreatic neuroendocrine tumor clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in East Hanover, NJ

See all ankylosing spondylitis clinical trials recruiting in East Hanover — not just this study.

Browse Ankylosing Spondylitis Trials in East Hanover →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in East Hanover?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · East Hanover, NJ